Microba Life Sciences Limited (MAP.AX)
- Previous Close
0.1600 - Open
0.1800 - Bid 0.1800 x --
- Ask 0.1900 x --
- Day's Range
0.1800 - 0.1900 - 52 Week Range
0.1500 - 0.4247 - Volume
344,355 - Avg. Volume
184,824 - Market Cap (intraday)
80.613M - Beta (5Y Monthly) 2.75
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.38
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, and Singapore. The company operates through two segments, Testing Services, and Research and Development. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; testing and data analysis services for personal and research testing; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases, as well as Databank for health and biome data. The company was incorporated in 2017 and is based in Brisbane, Australia.
microba.comRecent News: MAP.AX
Performance Overview: MAP.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MAP.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MAP.AX
Valuation Measures
Market Cap
80.61M
Enterprise Value
53.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.10
Price/Book (mrq)
1.64
Enterprise Value/Revenue
8.25
Enterprise Value/EBITDA
-3.26
Financial Highlights
Profitability and Income Statement
Profit Margin
-282.64%
Return on Assets (ttm)
-27.33%
Return on Equity (ttm)
-39.09%
Revenue (ttm)
6.54M
Net Income Avi to Common (ttm)
-18.49M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
28.05M
Total Debt/Equity (mrq)
2.80%
Levered Free Cash Flow (ttm)
-19.04M
Research Analysis: MAP.AX
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: MAP.AX
MAP.AX does not have Company Insights